EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY

被引：0
|
作者：
Rizk, Dana V. [1 ]
Kollins, Dmitrij [2 ]
Papachristofi, Olympia [2 ]
Hach, Thomas [2 ]
Jacinto-Sanders, Severina [2 ]
Merkel, Tobias [2 ]
Renfurm, Ronny [2 ]
Perkovic, Vlado [3 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ New South Wales, Kensington, NSW, Australia
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2024年 / 83卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
3
引用
收藏
页码：699 / 700
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study
    Perkovic, Vlado
    Kollins, Dmitrij
    Papachristofi, Olympia
    Hach, Thomas
    Jacinto-Sanders, Severina
    Merkel, Tobias
    Renfurm, Ronny
    Rizk, Dana V.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I255 - I256
  • [2] Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
    Rizk, Dana, V
    Rovin, Brad H.
    Zhang, Hong
    Kashihara, Naoki
    Maes, Bart
    Trimarchi, Hernan
    Perkovic, Vlado
    Meier, Matthias
    Kollins, Dmitrij
    Papachristofi, Olympia
    Charney, Alan
    Barratt, Jonathan
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (05): : 968 - 979
  • [3] A Phase 2a Study to Evaluate the Safety and Efficacy of Tegoprubart (AT-1501) in Patients With IgA Nephropathy (IgAN)
    Barratt, Jonathan
    Liew, Adrian
    Rizk, Dana
    Willcocks, Lisa
    Lafayette, Richard A.
    Wong, Muh Geot
    Tesar, Vladimir
    Bornstein, Jeffrey D.
    Reich, Heather N.
    Tang, Sydney C.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 187 - 188
  • [4] Interim analysis of a Phase 2 dose ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy
    Meier, Matthias
    Barratt, Jonathan
    [J]. SWISS MEDICAL WEEKLY, 2021, 151 : 2S - 2S
  • [5] COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSIS
    Mccafferty, Kieran
    Follman, Kristin
    Pasetti, Marcela
    Schachter, Asher
    Mathur, Mohit
    Diane, M. A.
    Yarbrough, Jill
    Shriver, Mallory
    Engler, Frank
    Oldach, David
    Suzuki, Yusuke
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I17 - I17
  • [6] IGA NEPHROPATHY (IGAN) SYMPTOMS AND DISEASE IMPACT: A LINGUISTIC ANALYSIS OF SOCIAL MEDIA CONVERSATIONS IN IGAN WITH PATIENTS, CAREGIVERS, AND HEALTHCARE PROVIDERS
    Dandy, Jennifer
    Batra, Akansha
    Morea, Erin
    Hargreaves, Will
    Donnini, Katie
    Oberdhan, Dorothee
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S83 - S84
  • [7] THE ROLE OF GLIADIN IN IGA NEPHROPATHY (IGAN) - AN IMMUNOPEROXIDASE STUDY OF BRITISH AND SINGAPORE PATIENTS
    DODD, S
    KHAN, TN
    MOORE, R
    SINNIAH, R
    [J]. JOURNAL OF PATHOLOGY, 1991, 163 (02): : A166 - A166
  • [8] SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS
    Barratt, Jonathan
    Heerspink, Hiddo Lambers
    Wong, Muh
    Komers, Radko
    Mercer, Alex
    Radhakrishnan, Jai
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I23 - I24
  • [9] INTERIM RESULTS FROM AN ONGOING PHASE 2 STUDY EVALUATING THE USE OF A MASP-2 INHIBITOR FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN)
    Barratt, Jonathan
    Leifke, Eckhard
    Whitaker, Steve
    DeTulleo, Louis
    Lafayette, Richard
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [10] SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL
    Rovin, Brad
    Barratt, Jonathan
    Murphy, Edward
    Geletka, Rob
    Komers, Radko
    Perkovic, Vlado
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S114 - S114
12345